A new, generic, non-steroidal anti-inflammatory drug (NSAID) is now available for managing osteoarthritis (OA) pain in horses ...

Enterotoxemia, also called “overeating disease” or “purple gut,” can cause the death of a young calf in as few as 12 hours, with signs that are not detectable ... professional services veterinarian, ...

With minimal clinical signs along with these reproductive inefficiencies ... especially in cow-calf operations,” said Jody Wade, DVM, Boehringer Ingelheim. “If cows aren’t able to produce a healthy ...

In addition to growth from Mounjaro, European revenue benefited from 1x payment associated with the amendment of our alliance with Boehringer Ingelheim. This was recorded in Jardiance revenue in Q4.

Patrick Dempsey will begin the VMX conference with his keynote address, sponsored by Boehringer Ingelheim. During the address ... diagnosis and clinical signs. The majority of the session will also ...

Objectives To determine the association between symptoms and signs reported in primary care consultations ... AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, CardioRenal, Cytokinetics, ...

Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...

Boehringer Ingelheim’s lung disease drug nerandomilast has been successful in a Phase III study paving the way for the company to seek approval for the asset in a second condition. Topline data ...

Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...

Boehringer Ingelheim announced that the FIBRONEER-ILD trial met its primary endpoint, which was the absolute change from baseline in FVC (mL) at week 52 versus placebo. FVC is a measure of lung ...